Lazard Asset Management
WST icon

Lazard Asset Management’s West Pharmaceutical WST Stock Holding History

Lazard Asset Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4
Closed -$1K – 2603
2024
Q4 		$1K Hold
4
– – ﹤0.01% 2247
2024
Q3 		$1K Hold
4
– – ﹤0.01% 2224
2024
Q2 		$1K Sell
4
-2
-33% -$707 ﹤0.01% 2195
2024
Q1 		$2K Sell
6
-6,117
-100% -$2.26M ﹤0.01% 1949
2023
Q4 		$2.15M Sell
6,123
-2,321
-27% -$821K ﹤0.01% 838
2023
Q3 		$3.17M Sell
8,444
-153
-2% -$59.2K ﹤0.01% 791
2023
Q2 		$3.29M Buy
8,597
+8,343
+3,285% +$2.98M ﹤0.01% 795
2023
Q1 		$87K Buy
254
+8
+3% +$2.34K ﹤0.01% 1588
2022
Q4 		$57K Buy
246
+87
+55% +$20.6K ﹤0.01% 1744
2022
Q3 		$38K Sell
159
-9,058
-98% -$2.76M ﹤0.01% 1909
2022
Q2 		$2.79M Sell
9,217
-21,092
-70% -$6.86M ﹤0.01% 841
2022
Q1 		$12.4M Sell
30,309
-2,832
-9% -$1.11M 0.01% 565
2021
Q4 		$15.5M Sell
33,141
-17,432
-34% -$7.5M 0.02% 535
2021
Q3 		$21.5M Sell
50,573
-70,872
-58% -$29.9M 0.02% 455
2021
Q2 		$43.6M Sell
121,445
-3,777
-3% -$1.25M 0.05% 311
2021
Q1 		$35.3M Sell
125,222
-4,981
-4% -$1.43M 0.04% 325
2020
Q4 		$36.9M Buy
130,203
+3,453
+3% +$969K 0.05% 321
2020
Q3 		$34.8M Buy
126,750
+13,095
+12% +$3.47M 0.05% 291
2020
Q2 		$25.8M Buy
113,655
+26,676
+31% +$5.24M 0.04% 326
2020
Q1 		$13.2M Sell
86,979
-2,185
-2% -$336K 0.02% 379
2019
Q4 		$13.4M Buy
+89,164
New +$13M 0.02% 408

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Lazard Asset Management's WST Position: Q1 2025 in Review

Lazard Asset Management sold out of West Pharmaceutical (WST) in Q1 2025, closing a stake of 4 shares — an estimated $1K sold.

Lazard Asset Management first reported a position in WST in Q4 2019 and held it in 21 quarters. The position peaked at $43.6M in Q2 2021. 715 funds tracked by Wall St. Rank hold WST as of Q1 2025.

  • Lazard Asset Management reported no remaining West Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 4 West Pharmaceutical shares in Q1 2025, an estimated $1K.
  • Lazard Asset Management first reported a position in West Pharmaceutical in Q4 2019 and held it in 21 quarters.
  • Lazard Asset Management's West Pharmaceutical position peaked at $43.6M in Q2 2021.
  • 715 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.